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Abstract
Effects of the commercial drug zanamivir (Relenza™) covalently attached to poly-L-glutamine on
the infectivity of influenza A viruses are examined using the plaque reduction assay and binding
affinity to viral neuraminidase (NA). These multivalent drug conjugates exhibit (i) up to a 20,000-
fold improvement in anti-influenza potency compared with the zanamivir parent against human
and avian viral strains, including both wild-type and drug-resistant mutants, and (ii) superior
neuraminidase (NA) inhibition constants, especially for the mutants. These findings provide a
basis for exploring polymer-attached inhibitors as more efficacious therapeutics, particularly
against drug-resistant influenza strains.
Keywords
drug resistance; polymeric drugs; zanamivir; influenza A; poly-L-glutamine; plaque reduction
assay; neuraminidase inhibition assay
INTRODUCTION
In addition to yearly outbreaks affecting hundreds of millions of people worldwide,1
influenza pandemics of animal–human reassortment strains are increasingly common.
Influenza infection is somewhat mitigated by prompt treatment with the neuraminidase (NA)
inhibitors, oseltamivir (Tamiflu™), and zanamivir (Relenza™).1 Sialic acid cleavage from
glycoproteins and glycolipids catalyzed by NA promotes both initiation of infection and
multicycle infection by preventing viral aggregation, cleaving viral receptors from infected
cells to allow release of newly formed virions, and degrading host’s mucins to enable access
to epithelial cell surfaces.2-4
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Point mutations in and around the active site of the NA enzyme can confer drug resistance
and contribute to widespread infection.5,6 New therapeutic agents designed to circumvent
drug resistance have been only moderately successful.6-9 An alternative strategy may be to
covalently conjugate small-molecule drugs to biocompatible and resorbable water-soluble
polymers. Although the resultant multivalent10 polymeric drugs have been shown to possess
a greatly enhanced potency against wild-type human strains of influenza virus,11 they have
not been explored against either mutant or nonhuman strains. In the present study, we fill
this void and demonstrate that zanamivir covalently attached to poly-L-glutamine can
overcome both oseltamivir and zanamivir resistance in not only human but also avian
influenza A strains.
MATERIALS AND METHODS
Poly-L-glutamic acid (molecular weight = 50,000–100,000 Da) and all other chemicals,
biochemicals, and solvents were purchased from Sigma-Aldrich Chemical Co (St. Louis,
Missouri, USA). Influenza viruses [A/Wuhan/359/95 (H3N2) and A/turkey/MN/833/80
(H4N2), as well as their drug-resistant mutants] were obtained from the Centers for Disease
Control and Prevention (Atlanta, Georgia, USA). Madin-Darby canine kidney (MDCK) cells
were purchased from the ATCC. Zanamivir (1, Fig. 1) was obtained from BioDuro (Beijing,
China).
Zanamivir derivative 2 (Fig. 1) was synthesized as described previously.12 To prepare
polymer conjugates 3–5 (Fig. 1), 2 was reacted with the benzotriazole ester of poly-L-
glutamic acid, followed by quenching with NH4OH (Fig. 2)11. Bare poly-L-glutamine was
synthesized analogously.11 Zanamivir content in 3–5 was quantified by 1H NMR.
Plaque assays were performed in 12-well plates using a modified literature procedure.12,13
First, 55-μL aliquots of virus preparation (~800 pfu/mL in PBS) were incubated with equal
volumes of inhibitor solutions (serially 10-fold diluted in PBS) for 1 h at room temperature.
After washing, MDCK cells grown to confluency were infected at room temperature for 1 h
with 100 μL of the virus–inhibitor mixture. The inoculum was removed by aspiration, and
the cells were overlaid with 1 mL of plaque medium12 [2×F12 medium, 0.01% DEAE-
dextran, 0.1% NaHCO3, 100 units/mL of penicillin G, 100 μg/mL of streptomycin, 4 μg/mL
of trypsin, and 0.6% purified agar (L28; Oxoid Co., Basingstoke, UK)]. Plaques were
counted after 3 to 4 days of incubation at 37°C.
Neuraminidase inhibition assays were performed using a modified literature procedure.14
Briefly, 20 μL of whole virus and 15 μL of inhibitor dilutions were incubated at room
temperature for 1 h. Following addition of the fluorogenic NA substrate 4-
methylumbelliferyl-α-D-N-acetylneuraminic acid (whose final concentration was 5- to 10-
fold lower than the Km of the enzyme), generation of 4-methylumbelliferone was monitored
for 1 h. Values of Ki were determined with nonlinear regression in KaleidaGraph.15
RESULTS AND DISCUSSION
To explore the benefits of multivalency10 (i.e., in the present case, covalent attachment of
multiple copies of zanamivir to the same polymeric chain) with respect to drug-resistant
strains, herein we have selected three influenza A viruses carrying NA mutations at position
119: two in vitro selected zanamivir-resistant16 avian A/turkey/MN/833/80 (turkey/MN;
H4N2) E119D and E119G mutants and a clinically isolated oseltamivir-resistant A/Wuhan/
359/95 (Wuhan; H3N2) E119V mutant, which is transmissible in ferrets.17
We have synthesized water-soluble polymeric derivatives of 1 in which the drug is
conjugated to poly-L-glutamine through a flexible tether (Fig. 1).11,12 The introduction of the
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linker group did not drastically affect the anti-influenza or NA inhibitory activity. The
inhibitory potency of 2 is within an order of magnitude of 1’s (Table 1), as well as of other
zanamivir derivatives modified at the same position.18,19
Inhibition of influenza A/Yamagata (H1N1) is most effective with a 10% loading of
zanamivir on poly-L-glutamine11; other multivalent systems reach a plateau in efficacy
between 10% and 30% modification.20 Therefore, we have selected 10 mol% loading for
our initial experiments as well. Using the plaque reduction assay, we have demonstrated that
the poly-L-glutamine-attached drug 4 is not only about 20,000-fold more effective than 2
against another human influenza strain, Wuhan, but also some 200-fold more potent against
an avian strain, turkey/MN.
Importantly, both oseltamivir- and zanamivir-resistant mutants of these viral strains are also
far more susceptible to polymeric 4 than to small-molecule inhibitor 2: some 6000-fold
improvement against oseltamivir-resistant Wuhan E119V mutant and a 2000-fold more
enhancement against zanamivir-resistant turkey/MN mutants have been observed (Fig. 3). In
comparison, maximal improvements for novel monomeric inhibitors to date have not
exceeded 1000 times against oseltamivir-resistant influenza strains9 and 250 times against
zanamivir-resistant ones.6
Next, we have examined how the amount of 2 conjugated to poly-L-glutamine affects
inhibitory potency. Polymeric 4 has been found to be 10-fold more potent than either 3 or 5
against wild-type strains of both human Wuhan and avian turkey/MN viruses (Table 1).
Importantly, 4 is also up to 20 times more potent than either 3 or 5 at inhibiting the drug-
resistant strains (Table 1). The observation of the same optimal degree of loading for all the
viral strains tested by us suggests that beyond a certain point the benefits of multivalency are
counteracted by steric hindrances—presumably, too many ligand molecules attached to the
same polymer chain interfere with each other’s action.
To gain further mechanistic insights, we have determined inhibition constants Ki for both 4
and 2, using the NA enzyme inhibition assay. The results presented in Table 2 afford several
important conclusions. First, as seen in the last two lines of the table, the enzymes of
zanamivir-resistant influenza strains expectedly bind 2 at least two orders of magnitude
weaker than the wild-type and oseltamivir-resistant strains. Second, in all instances, the
polymer-attached drug is a substantially more potent enzyme inhibitor than its small-
molecule parent. Third, while the binding affinity enhancements caused by conjugation to
poly-L-glutamine are relatively modest for wild-type human and avian strains, as well as for
the oseltamivir-resistant human one, zanamivir-resistant turkey/MN mutants bind 4 2000
times more stronger than 2. As a result of this strengthened binding, the zanamivir-resistant
mutants become as sensitive to 4 (in contrast to 2) as the others (Table 2). Thus, presentation
of zanamivir on the polymer completely compensates for weakened binding in zanamivir-
resistant strains.
Multivalent drug species, such as 4, exhibit better virus inhibition because of steric effects
and increased affinity.10 Flexible linkers, such as that employed in this study, can promote
improved ligand–protein binding by reducing steric obstacles and increasing effective ligand
concentration21 (as is schematically illustrated in Fig. 4). Both free and polymer-bound 1
should have similar rotational and translational entropic costs for the first interaction with
viral surface proteins but polymer-bound 1 should have lower costs for subsequent ones,
thereby providing entropic benefits of multivalency.22 Herein, we have demonstrated that a
multivalent presentation of 1 conjugated to a resorbable polymeric backbone overcomes
binding deficiencies and leads to potent inhibition not only of wild-type but also of drug-
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resistant human and avian influenza strains, thus promising safe and more efficacious
therapeutics.
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Figure 1.
Chemical structures of zanamivir (1), its derivative for attachment to poly-L-glutamic acid
(2), and polymer-attached 2 at different degrees of loading (3–5).
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Figure 2.
Preparation of drug–polymer conjugates 3, 4, and 5. HOBt, 1-hydroxybenzotriazole; EDC,
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide; DMF, N, N-dimethylformamide.
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Figure 3.
Antiviral activity enhancements of polymeric 4 over small-molecule 2 against wild-type and
drug-resistant influenza strains. To determine the underlying IC50 values, zanamivir-based
inhibitors and viruses were incubated together prior to infection of confluent MDCK cells.
The antiviral activity enhancements shown were the results of experiments run at least in
triplicate. The only exceptions were the A/turkey/MN mutants where a single measurement
was run because of the large quantities of 2 required. An IC50 value for these zanamivir-
resistant mutants was not reached event at millimolar concentrations of 2; thus, the actual
enhancements are at least those indicated.
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Figure 4.
Schematic illustration of the proposed interactions of target viral surface proteins (gray
claws) with complementary drugs (black ovals) in rigid (a) and flexible (b) drug–polymer
conjugates. The large gray spheres represent influenza virus particles and black lines the
polymeric chain and linkers.
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Table 2
Inhibition Constants (Ki) of Viral Neuraminidases by Small-Molecule (2) and Polymeric (4) Zanamivir
Derivatives Against Both Wild-Type and Drug-Resistant Human and Avian Influenza Strains
Ki (nM of Zanamivira)
Strain 2 4
A/Wuhan/359/95 3.1 ± 1.0 0.93 ± 0.12
A/Wuhan/359/95 E119V 1.9 ± 0.8 0.90 ± 0.10
A/turkey/MN/833/80 4.6 ± 0.9 0.27 ± 0.16
A/turkey/MN/833/80 E119D 800 ± 150 0.37 ± 0.12
A/turkey/MN/833/80 E119G 370 ± 20 0.13 ± 0.05
a
All values were determined from experiments run at least in triplicate unless otherwise indicated. The Ki values are expressed in concentrations of
zanamavir, whether free or conjugated to poly-L-glutamine. For other conditions, see the Materials and Methods section.
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